EFFECTS OF REBOXETINE & NEFAZODONE ON PHARMACOKINETICS OF ALPRAZOLAM

Reboxaline是一种选择性去甲肾上腺素再摄取抑制剂，是一种研究性抗抑郁药，已被批准在几个欧洲国家使用，其NDA将提交给FDA批准。 一旦获得批准，它将加入一系列抗抑郁药，这些抗抑郁药在很大程度上取代了三环类抗抑郁药。 本研究的目的是确定阿普唑仑（一种部分由CYP3A4同工酶控制代谢的药物）的药代动力学和药效学是否因给予被认为抑制CYP3A4的瑞波西汀而改变。 瑞波西汀对阿普唑仑的作用也将与奈法唑酮（一种血清素摄取抑制剂）进行比较。

Reboxetine, a selective norepinepherine reuptake inhibitor, is an investigational antidepressant which is approved for use in several European countries and for which an NDA will be submitted to the FDA for approval. Once approved, it will join an array of antidepressants which have largely replaced the tricyclic antidepressants. The purpose of this study is to determine whether the pharmacokinetics and pharmacodynamics of alprazolam, a drug whose metabolism is mandated in part by the CYP3A4 isoenzyme, is altered by the administration of reboxetine which is thought to inhibit CYP3A4. The effect of reboxetine on alprazolam will also be compared to that of nefazodone, a seratonin-uptake inhibitor.